

Kimberly H Allison, MD

**Director of Breast Pathology
Program Director of Anatomic Pathology Residency Program
Director of Breast Pathology Fellowship
Professor, Department of Pathology
Stanford University School of Medicine
300 Pasteur Drive, Lane L235
Stanford, CA 94305
650-724-6194
allisonk@stanford.edu**

Dr. Allison is the Director of Breast Pathology at Stanford. Her research interests include prognostic/predictive markers in breast cancer, standards in HER2 and ER testing, management of risk lesions, diagnostic criteria and diagnostic agreement in breast pathology and patient communication. She is on the editorial board for the 5th edition of the WHO Classification of Tumours of the Breast, is co-chair of the ASCO/CAP ER/PR Testing in Breast Cancer committee, was on the steering committee for the 2018 ASCO/CAP HER2 Testing Guidelines Update, and serves on the NCCN Breast Cancer Treatment Guidelines committee. She is actively involved in resident/fellow training as Director of the Stanford Breast Pathology Fellowship and Residency Director for the Department of Pathology.

Date of Birth: October 28, 1974 Washington D.C.
Citizenship: USA

EDUCATION

9/1993-5/1997 Princeton University, Department of Molecular Biology
Princeton, NJ
9/1997-5/2001 New York Medical College
Valhalla, NY

DEGREES

1997 B.A. Princeton University (Magna Cum Laude)
2001 M.D. New York Medical College (AOA)

POSTGRADUATE TRAINING

7/2001-6/2006 Anatomic and Clinical Pathology Residency/Fellowship
University of Washington
Seattle, Washington
7/2004-6/2005 Surgical Pathology Fellowship
*Focused year on breast and gynecologic pathology
University of Washington
Seattle, Washington

FACULTY POSITIONS

9/2017-	Professor, Department of Pathology, Stanford University School of Medicine
3/2015 -	Director of Breast Pathology, Stanford University School of Medicine
1/2013-9/2017	Associate Professor, Department of Pathology, Stanford University School of Medicine
7/2012-12/2012	Associate Professor, Director of Breast Pathology Service, Department of Anatomic Pathology, University of Washington Medical Center
8/2008-7/2012	Assistant Professor, Director of Breast Pathology Service, Department of Anatomic Pathology, University of Washington Medical Center
8/2006 -6/2008	Acting Instructor, Department of Anatomic Pathology, University of Washington Medical Center

BOARD CERTIFICATION

2006	Board certified in Anatomic and Clinical Pathology (recertified in 2016)
------	--

LICENSURE

2013-current	Physician and Surgeon, State of California
2004-2013	Physician and Surgeon, State of Washington

SPECIAL RESPONSIBILITIES

International:

- 2018 Member of the WHO Classification of Tumours 5th edition Editorial Board
- 2018 Member of Editorial Board for Histopathology
- 2015 Member of International Consortium for Health Outcomes Measurement Breast Cancer Working Group
- 2014 Member of the International TILs Working Group in Breast Cancer

National:

- 2018 Co-chair of the CAP/ASCO ER and PR Testing in Breast Cancer Guidelines Committee
- 2016- Steering Committee member of the CAP/ASCO HER2 Testing in Breast Cancer Guidelines Committee
- 2018 Member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Clinical Practice Guidelines Committee
- 2017 Member of the CAP/ASCO Quantitative Image Analysis of HER2 Immunohistochemistry in Breast Cancer Guidelines Committee
- 2016 Advisory Board Member for American Society of Clinical Pathology Patient Ambassador Program
- 2015 Member of the ASCO Guideline Endorsement Panel for the Cancer Care Ontario Recommendations on the Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early Stage, Operable Breast Cancer
- 2015 Section Editor for Breast Education and Self-Assessment Program (BESAP) for the American Society of Breast Surgeons
- 2013 Member of the CAP/ASCO HER2 Testing in Breast Cancer Guidelines Committee Update Panel (Patient Communication)
- 9/2011- Member of TCGA Expert Breast Pathology Committee for NCI/NIH Cancer Genome Atlas project
- 1/2012-5/2012 Genentech Speakers Bureau Member (HER2 Testing)
- 2011-2013 College of American Pathologists Spokesperson
- 7/2004-6/2005 WA State Resident Delegate, College of American Pathologists

Institutional:

- 3/2015 - Director of Breast Pathology, Stanford University School of Medicine
- 7/2016 - Director of the Stanford Breast Pathology Fellowship
- 5/2017- Pathology Residency Program Director
- 2017- Advisory committee member for Stanford Cancer Institute Tissue Bank
- 1/2013-5/2017 Associate Program Director of Anatomic Pathology Residency Program, Stanford University School of Medicine
- 1/2013-6/2016 Co-director of Stanford Breast/GYN Pathology Fellowship
- 1/2016- Member of search committee for Stanford OB/GYN chair
- 9/2016-6/2017 Invited participant in Stanford Leadership Development Program

9/2016-	Member of Teaching and Training Committee, Stanford Department of Pathology
2/2017 -	Member of the Faculty Unity and Nurturing committee
3/2008-12/2012	Director of Breast Pathology, UWMC
7/2011-12/2012	Associate Program Director of Pathology Residency Program, UWMC
7/2010-12/2012	Director, Breast/Gyn Pathology fellowship, UWMC (2008-2010 Co-Director)
7/2011-12/2012	Director of Clinical Research Fellowship, UWMC
7/2011-12/2012	Co-director of Resident Research Fund
9/2011-5/2012	Member of search committee for Chair of Pathology, UWMC
9/2010-12/2012	Investigator/co-lead of UW/Fred Hutchinson Cancer Consortium Biospecimen Program
7/2007-7/2011	Co-Director, medical student elective rotation in Anatomic Pathology UWMC
7/2006-12/2012	Pathology review/presentation of cases, twice weekly Breast Tumor Boards at Seattle Cancer Care Alliance
7/2010- 12/2012	Review committee for Roger E Moe Fellowship in Multidisciplinary Breast Cancer Care
3/2009-12/2012	Member of UW Medicine Ambulatory Network Development Committee
7/2007- 7/2009	Pacific Ovarian Cancer Research Consortium/SPORE in Ovarian Carcinoma at Fred Hutchinson Cancer Consortium Co-leader, Specimen/Tissue Core Member, Specimen Use Committee
7/2004-6/2005	Member, Anatomic Pathology Compliance Committee UW Medicine
7/2004-6/2006	Resident Representative, Pathology Residency Management Committee UW Medicine

ORGANIZATIONS AND BOARDS

United States-Canadian Academy of Pathologists
College of American Pathologists
Expedition Inspiration, Board of Directors (2011-2013)
Bold for the Cure, Board of Directors (2011-2014)

HONORS

2010	Young Investigator Award for Breast Cancer Research from Safeway
2000-2001	Alpha Omega Alpha honor society, New York Medical College
2001	Award of Distinction, New York Medical College
1997	E.R. Squibb and Sons Senior Thesis Prize for contributions to scientific research, Princeton University
1997	Sigma Xi scientific research society member

Ad Hoc article peer review for:

Journal of Clinical Oncology

Journal of the National Cancer Institute
Clinical Cancer Research
Breast Cancer Research and Treatment
Histopathology
Modern Pathology
Archives of Pathology and Laboratory Medicine
American Journal of Clinical Pathology
Journal of the National Cancer Institute
Pathology Research and Practice
Hormones and Cancer

PUBLICATIONS:

Original Peer Reviewed Studies

1. Miller RK, **Heller KK (Allison)**, Frisen L, Wallack DL, Loayza D, Gammie AE, Rose MD. The kinesin-related proteins, Kip2p and Kip3p, function differently in nuclear migration in yeast. *Mol Biol Cell* 1998; 9:2051-2068.
2. **Allison KH**, Yoder BJ, Bronner MP, Goldblum JR, Rubin BP. Angiosarcoma involving the gastrointestinal tract: a series of primary and metastatic cases. *Am J Surg Pathol* 2004 Mar; 28(3):298-307.
3. **Allison KH**, Fligner CL, Park WT. Radiographically occult diffuse intra-sinusoidal hepatic metastases from primary breast carcinomas: a clinicopathologic study of three autopsy cases. *Arch Pathol Lab Med* 2004 Dec;128(12):1418-1423.
4. Abadie JM, **Allison KH**, Black DA, Garbin J, Saxon AJ, Bankson DD. Can an immunoassay become a standard technique in detecting oxycodone and its metabolites? *J Anal Toxicol* 2005 Nov-Dec;29(8):825-829.
5. **Allison KH**, Patel RM, Goldblum JR, Rubin BP. Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis. *Am J Clin Pathol* 2005 Nov; 124(5):685-692.
6. Pugliese MS, Kohr JR, **Allison KH**, Wang NP, Tickman RJ, Beatty JD. Accuracy of intraoperative imprint cytology of sentinel lymph nodes in breast cancer. *Am J Surg* 2006 Oct; 192(4):516-519.
7. Willner J, **Allison KH**, Galic V, Garcia R, Goff B, Swisher EM. Alternate molecular pathways leading to common histologies in ovarian epithelial cancer. *Hum Pathol* 2007 Apr; 38(4):607-613.
8. **Allison KH**, Swisher EM, Garcia RL. Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is a full staging procedure unnecessary? *Int J Gynecol Pathol* 2008 Jan; 27(1):10-17.

9. Shah CA, **Allison KH**, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells and tumor-associated macrophages: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. *Gynecol Oncol* 2008 May; 109(2):215-219.
10. **Allison KH**, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL. Diagnosing endometrial hyperplasia: why is it so difficult to agree? *Am J Surg Pathol* 2008 May; 32(5):691-698.
11. Eby PR, JE Ochsner, WB DeMartini, **KH Allison**, S Peacock, CD Lehman. Is surgical excision necessary for focal atypical ductal hyperplasia found at stereotactic vacuum-assisted breast biopsy? *Ann Surg Oncol* 2008 Nov;15(11):3232-3238.
12. Bohling SD, **Allison KH**. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. *Mod Pathol* 2008 Dec; 21(12):1527-32.
13. Pugliese MS, Beatty JD, Tickman RJ, **Allison KH**, Atwood MK, Szymonifka J, Arthurs ZM, Huynh PP, Dawson JH. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. *Ann Surg Oncol* 2009 Jan; 16(1):113-120 [Epub 2008 Oct 23].
14. Eby PR, Ochsner JE, DeMartini WB, **Allison KH**, Peacock S, Lehman CD. Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge. *AJR Am J Roentgenol* 2009 Jan; 192(1):229-234.
15. Reed SD, Newton KM, Clinton WL, Epplein M, Garcia R, **Allison K**, Voigt LF, Weiss NS. Incidence of endometrial hyperplasia. *Am J Obstet Gynecol* 2009; 200:678.e1-6.
16. Reed SD, Voight LF, Newton KM, Garcia RH, **Allison HK (sic)**, Epplein M, Jordan D, Swisher E, Weiss NS. Progestin therapy of complex endometrial hyperplasia with and without atypia. *Obstet Gynecol* 2009; 113:655-662.
17. Partridge SC, Murthy R, Ziadloo A, White SW, **Allison KH**, Lehman CD. Diffusion tensor MRI of the normal breast. *Magn Reson Imaging* 2010 Apr; 28(3):320-328.
18. Strigel RM, Eby PR, DeMartini WB, Gutierrez RL, **Allison KH**, Peacock S, Lehman CD. Frequency, upgrade rates and characteristics of high risk lesions initially identified with breast MRI. *AJR Am J Roentgenol* 2010 Sep; 195(3):792-798.
19. Kohr JR, Eby PR, **Allison KH**, Demartini WB, Gutierrez RL, Peacock S, Lehman CD. Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications. *Radiology* 2010 Jun; 255(3):723-730.

20. Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, **Allison KH**, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by PET varies by tumor subtype in locally advanced breast cancer. *Clin Cancer Res* 2010 May; 16(10):2803-2810.
21. Reed SD, Newton KM, Garcia RL, **Allison KH**, Voigt LF, Jordan CD, Epplein M, Swisher E, Upson K, Ehrlich KJ, Weiss NS. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. *Obstet Gynecol* 2010 Aug; 116(2 Pt 1):365-373.
22. Grimm EE, Schmidt RA, Swanson PE, **Allison KH**. Achieving 95% IHC/FISH concordance for Her2: causes and implications of discordant cases. *Am J Clin Pathol* 2010 Aug; 134(2):284-292.
23. Norquist BM, Garcia RL, **Allison KH**, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. *Cancer* 2010 Nov; 116(22):5261-71.
24. Wu JM, Beck AH, Pate LL, Witten D, Zhu S, Montgomery KD, **Allison KH**, van de Rijn M, West R. Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes. *Clin Cancer Res*, Clin Cancer Res. 2011 Feb 1;17(3):437-46. Epub 2010 Nov 22.
25. **Allison KH**, Eby PR, Kohr J, DeMartini WB, Lehman CD. Atypical ductal hyperplasia on vacuum assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk of upgrade. *Hum Pathol* 2011 Jan; 42(1):41-50.
26. Press JZ, **Allison KH**, Garcia R, Everett EN, Pizer E, Swensen RE, Tamimi HK, Gray HJ, Peters WA 3rd, Goff BA. FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence. *Gynecol Oncol* 2011 Feb;120(2):296-9.
27. Anastas JN, Biechele TL, Robitaille M, Muster J, **Allison KH**, Angers S, Moon RT. A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression. *Oncogene* 2011 Dec. [Epub ahead of print]
28. **Allison KH**, Dintzis DM, Schmidt RA. Frequency of HER2 Heterogeneity by Fluorescence in Situ Hybridization According to CAP Expert Panel Recommendations; Time for a new look at how to report heterogeneity. *AJCP* 2011 Dec;136(6):864-71
29. **Allison KH**, Kandalaf PL, Sitlani C, Dintzis SM, Gown AM, Goldstein LC. Routine pathologic parameters can predict Oncotype DX™ recurrence scores in subsets of ER positive patients; who does not need testing? *Breast Cancer Res Treat*. 2012 Jan; 131(2):413-24.

30. **Allison KH**, Reed SD, Upson K, Voigt LF, Jordan CD, Newton KM, Garcia RL. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. *Int J Gynecol Pathol* 2012 Mar;31(2):151-9.
31. Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, **Allison KH**. Lobular In-Situ Neoplasia on Breast Core Needle Biopsy: Imaging Indication and Pathologic Extent Can Identify Which Patients Require Excisional Biopsy. *Ann Surg Oncol* 2012 Mar;19(3):914-21.
32. Rahbar H, Partridge SC, Demartini WB, Gutierrez RL, **Allison KH**, Peacock S, Lehman CD. In vivo assessment of ductal carcinoma in situ grade: a model incorporating dynamic contrast-enhanced and diffusion-weighted breast MR imaging parameters. *Radiology* 2012 May; 263(2):374-82.
33. Kurland BF, Gadi VK, Specht JM, **Allison KH**, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. *EJNMMI Res* 2012 Jun 25;2(1):34. Doi: 10.1186/2191X-2-34.
34. Upson K, **Allison KH**, Reed SD, Jordan CD, Newton KM, Swisher EM, Doherty JA, Garcia RL. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. *Am J Obstet Gynecol* 2012 Jul;207(1)36.e1-8. Epub 2012 May 16.
35. Parsian S, Rahbar H, **Allison KH**, Demartini WB, Olson ML, Lehman CD, Partridge SC. Nonmalignant Breast Lesions: ADCs of Benign and High-Risk Subtypes Assessed as False-Positive at Dynamic Enhanced MR Imaging. *Radiology*. 2012 Dec;265(3):696-706
36. Raghunath V, Braxton MO, Gagnon SA, Bruny  TT, **Allison KH**, Reisch LM, Weaver DL, Elmore JG, Shapiro LG. Mouse cursor movement and eye tracking data as an indicator of pathologists' attention when viewing digital whole slide images. *J Pathol Inform*. 2012;3:43. doi: 10.4103/2153-3539.104905
37. Oster NV, Carney PA, **Allison KH**, Weaver DL, Reisch LM, Longton G, Onega T, Pepe M, Geller BM, Nelson HD, Ross TR, Tosteson AN, Elmore JG. Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS). *BMC Womens Health*. 2013 Feb 5;13:3. doi: 10.1186/1472-6874-13-3.
38. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, **Allison KH**, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol*. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984 PMID:24101045

39. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, **Allison KH**, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology; College of American Pathologists clinical practice guideline update. *Arch Pathol Lab Med*. 2014 Feb; 138(2):241-256. Doi: 10.5858/arpa.2013-0953-SA. Epub 2013 Oct 7.
40. **Allison KH**, Reisch LM, Carney PA, Weaver DL, Schnitt SJ, O'Malley FP, Geller BM, Elmore JG. Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel. *Histopathology*. 2014 Aug;65(2):240-251. doi: 10.1111/his.12387. PMID: 24511905
41. Loiselle C, Eby PR, Kim JN, Calhoun KE, **Allison KH**, Gadi VK, Peacock S, Storer BE, Mankoff DA, Partridge SC, Lehman CD. Preoperative MRI improves prediction of extensive occult axillary lymph node metastases in breast cancer patients with a positive sentinel lymph node biopsy. *Acad Radiol*. 2014 Jan;21(1):92-8. doi: 10.1016/j.acra.2013.10.001. PMID: 24331270
42. Onega T, Weaver D, Geller B, Oster N, Tosteson AN, Carney PA, Nelson H, **Allison KH**, O'Malley FP, Schnitt SJ, Elmore JG. Digitized whole slides for breast pathology interpretation: current practices and perceptions. *J Digit Imaging*. 2014 Oct;27(5):642-648. doi: 10.1007/s10278-014-9683-2. PubMed PMID: 24682769.
43. Clay MR, **Allison KH**, Folkins AK, Longacre TA. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency. *Am J Surg Pathol*. 2014 Nov;38(11):1494-1500. Doi 10.1097/PAS.0000000000000259. 2014 Jun 11. PubMed PMID: 24921635
44. Chaudhuri O, Koshy ST, Branco da Cunha C, Shin JW, Verbeke CS, **Allison KH**, Mooney DJ. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. *Nat Mater*. 2014 Oct;13(10):970-8. doi: 10.1038/nmat4009. Epub 2014 Jun 15. PubMed PMID: 24930031.
45. Feng S, Weaver DL, Carney PA, Reisch LM, Geller BM, Goodwin A, Rendi MH, Onega T, **Allison KH**, Tosteson AN, Nelson HD, Longton G, Pepe M, Elmore JG. A framework for evaluating diagnostic discordance in pathology discovered during research studies. *Arch Pathol Lab Med*. 2014 Jul;138(7):955-61. doi:10.5858/arpa.2013-0263-OA. PubMed PMID: 24978923; PubMed Central PMCID:PMC4146522.
46. Geller BM, Nelson HD, Carney PA, Weaver DL, Onega T, **Allison KH**, Frederick PD, Tosteson AN, Elmore JG. Second opinion in breast pathology: policy, practice and perception. *J Clin Pathol*. 2014 Nov;67(11):955-60. doi: 10.1136/jclinpath-2014-202290.. [Epub ahead of print] PubMed PMID: 25053542.
47. Bruny  TT, Carney PA, **Allison KH**, Shapiro LG, Weaver DL, Elmore JG. Eye movements as an index of pathologist visual expertise: a pilot study. *PLoS One*. 2014

Aug 1;9(8):e103447. doi: 10.1371/journal.pone.0103447. eCollection 2014. PubMed PMID: 25084012; PubMed Central PMCID: PMC4118873.

48. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, **Allison KH**, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. *Ann Oncol*. 2015 Feb;26(2):259-71. Doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11. PMID: 25214542.
49. Cloyd JM, Yang RL, **Allison KH**, Norton JA, Hernandez-Boussard T, Wapnir IL. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. *Breast Cancer Res Treat*. 2014 Dec;148(3):637-44. doi: 10.1007/s10549-014-3207-0. Epub 2014 Nov 16. PMID: 25399232.
50. **Allison KH**, Abraham LA, Weaver DL, Tosteson AN, Nelson HD, Onega T, Geller BM, Kerlikowske K, Carney PA, Ichikawa LE, Buist DS, Elmore JG. Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium. *Cancer*. 2015 May 1;121(9):1369-78. doi:10.1002/cncr.29199. Epub 2015 Jan 20.
51. Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson AN, Nelson HD, Pepe MS, **Allison KH**, Schnitt SJ, O'Malley FP, Weaver DL. Diagnostic concordance among pathologists interpreting breast biopsy specimens. *JAMA*. 2015 Mar 17;313(11):1122-32. doi: 10.1001/jama.2015.1405.
52. Ciriello G, Gatz ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, **Allison KH**, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA; TCGA Research Network, Perou CM. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer Cell. 2015 Oct 8;163(2):506-19. doi: 10.1016/j.cell.2015.09.033.
53. Frederick PD, Nelson HD, Carney PA, Brunyé TT, **Allison KH**, Weaver DL, Elmore JG. The Influence of Disease Severity of Preceding Clinical Cases on Pathologists' Medical Decision Making. *Med Decis Making*. 2016 Apr 1. pii: 0272989X16638326. (Epub ahead of print) PMID 27037007.
54. Elmore JG, Nelson HD, Pepe MS, Longton GM, Tosteson AN, Geller B, Onega T, Carney PA, Jackson SL, **Allison KH**, Weaver DL. Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. *Ann Intern Med*. 2016 May 17;164(10):649-55. doi: 10.7326/M15-0964. Epub 2016 Mar 22.
55. Xu Y, Miyake KK, Liu TI, Downey JR, Lipson JA, **Allison KH**, Ikeda DM. The Milky Way Sign: A New Diagnostic Finding of Ductal Carcinoma in situ on Digital Breast

Tomosynthesis. *Breast J.* 2016 May;22(3):349-51. doi: 10.1111/tbj. 12583. Epub 2016 Mar 2.

56. Elmore JG, Tosteson AN, Pepe MS, Longton GM, Nelson HD, Geller B, Carney PA, Onega T, **Allison KH**, Jackson SL, Weaver DL. Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology simulation study. *BMJ.* 2016 Jun 22;353:i3069. doi: 10.1136/bmj.i3069. PMID: 27334105
57. Henry NL, Somerfield MR, Abramson VG, **Allison KH**, Anders CK, Chingos DT, Hurria A, Openshaw TH, Krop IE. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage Operable Breast Cancer. American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. *J Clin Oncol.* 2016 Jul 1;34(19) 2303-11. doi: 10.1200/JCO.2015.65.8609. Epub 2016 Mar 21.
58. Carney PA, **Allison KH**, Oster NV, Frederick PD, Morgan TR, Geller BM, Weaver DL, Elmore JG. Identifying and processing the gap between perceived and actual agreement in breast pathology interpretation. *Mod Pathol.* 2016 Jul;29(7):717-26. doi: 10.1038/modpathol.2016.62. Epub 2016 Apr 8.
59. Brunyé TT, Eddy MD, Mercan E, **Allison KH**, Weaver DL, Elmore JG. Pupil diameter changes reflect difficulty and diagnostic accuracy during medical image interpretation. *BMC Med Inform Decis Mak.* 2016 Jul5;16(1):77. PMID: 27378371.
60. **Allison KH**, Rendi MH, Peacock S, Morgan T, Elmore JG, Weaver DL. Histologic features associated with diagnostic agreement in atypical ductal hyperplasia of the breast: illustrative cases from the B-Path Study. *Histopathology*, 2016 Jul 11 [Epub ahead of print] (PMID:27398812).
61. Ballard M, Jalikis F, Krings G, Schmidt RA, Chen YY, Rendi MH, Dintzis SM, Jensen KC, West RB, Sibley RK, Troxell ML, **Allison KH**. 'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study. *Mod Pathol.* 2016 Oct 14. doi: 10.1038/modpathol.2016.175. PMID: 27739440
62. Heng YJ, Lester SC, Tse GM, Factor RE, **Allison KH**, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, Tan PH, Korski K, Waldman FM, Gutman DA, Sanders M, Reis-Filho JS, Flanagan SR, Gendoo DM, Chen GM, Haibe-Kains B, Ciriello G, Hoadley KA, Perou CM, Beck AH. The molecular basis of breast cancer pathologic phenotypes. *J Pathol* 2016 Nov 14. [Epub ahead of print] Doi: 10.1002/path.4847. PMID: 27861902
63. Jackson SL, Frederick PD, Pepe MS, Nelson HD, Weaver DL, **Allison KH**, Carney PA, Geller BM, Tosteson AN, Onega T, Elmore JG. Diagnostic reproducibility: What happened when the same pathologist interprets the same breast biopsy specimen at two points in time? *Ann Surg Oncol.* 2016 Dec 2. [Epub ahead of print] PMID: 27913946
64. Ong WL, Schouwenburg MG, van Bommel ACM, Stowell C, **Allison KH**, Benn KE, Browne JP, Cooter RD, Delany GP, Duhoux FP, Ganz PA, Hancock P, Jaggi R, Knaul F,

Knip AM, Koppert LB, Kuerer HM, McLaughlin S, Mureau MAM, Partidge AH, Reid DP, Sheeran L, Smith TJ, Stoutjesdijk MJ, Vrancken Peeters MJ, Wengstrom Y, Yip CH, Saunders C. Development of standard set of value-based patient-centered outcomes for breast cancer – the International Consortium for Health Outcomes Measurement (ICHOM) initiative. *JAMA Oncol.* 2016 Dec 29. doi: 10.1001/jamaoncol.2016.4851. [Epub ahead of print] PMID:28033439

65. Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, Waisman J, **Allison KH**, Dang Y, Disis ML. Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial. *JAMA Oncol.* 2017 Jan 19. doi: 10.1001/jamaoncol.2016.6007. [Epub ahead of print] PMID:28114604
66. Lin Chieh-Yu, Carneal EE, Lichtensztajn DY, Gomez SL, Clarke CA, Jensen KC, Kurian AW, **Allison KH**. Regional Variability in Percent of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks. *Am J Clin Pathol.* 2017 Sep 1;148(3):199-207. doi: 10.1093/ajcp/axq063. PMID: 28821197
67. Elmore JG, Longton GM, Pepe MS, Carney PA, Nelson HD, **Allison KH**, Geller BM, Onega T, Tosteson AN, Mercan E, Shapiro LG, Brunyé TT, Morgan TR, Weaver DL. A Randomized Study Comparing Digital Imaging to Traditional Glass Slide Microscopy for Breast Biopsy and Cancer Diagnosis. *J Pathol Inform.* 2017 Mar 10;8:12. doi: 10.4103/2153-3539.201920. eCollection 2017. PMID:28382226
68. Geller BM, Nelson HD, Weaver DL, Frederick PD, **Allison KH**, Onega T, Carney PA, Tosteson ANA, Elmore JG. Characteristics associated with requests by pathologists for second opinions on breast biopsies. *J Clin Pathol.* 2017 Nov;70(11):947-953. doi: 10.1136/jclinpath-2016-204231. Epub 2017 May 2. PMID: 28465449
69. Samples LS, Rendi MH, Frederick PD, **Allison KH**, Nelson HD, Morgan TR, Weaver DL, Elmore JG. Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens. *Breast.* 2017 Aug;34:34-43. doi: 10.1016/j.breast.2017.04.004. Epub 2017 May 3. PMID: 28475933
70. Onega T, Weaver DL, Frederick PD, **Allison KH**, Tosteson ANA, Carney PA, Geller BM, Longton GM, Nelson HD, Oster NV, Pepe MS, Elmore JG. The diagnostic challenge of low-grade ductal carcinoma in situ. *Eur J Cancer.* 2017 Jul;80:39-47. doi: 10.1016/j.ejca.2017.04.013. Epub 2017 May 20. PMID:28535496
71. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N,

Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, **Allison KH**, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Adv Anat Pathol.* 2017 Sep;24(5):235-251. doi: 10.1097/PAP.000000000000162.PMID: 28777142

72. Tosteson ANA, Yang Q, Nelson HD, Longton G, Soneji SS, Pepe M, Geller B, Carney PA, Onega T, **Allison KH**, Elmore JG, Weaver DL. Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs. *Breast Cancer Res Treat.* 2017 Sep 6. doi: 10.1007/s10549-017-4432-0. [Epub ahead of print] PMID:28879558
73. Fasola CE, Chen JJ, Jensen KC, **Allison KH**, Horst KC. Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. *Breast J.* 2017 Sep 19. doi: 10.1111/tbj.12843. [Epub ahead of print] PMID:28929550
74. Wolff AC, Hammond MEH, **Allison KH**, Harvey BE, McShane LM, Dowsett M. HER2Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. *J Oncol Pract.* 2018 Jul;14(7):437-441. doi: 10.1200/JOP.18.00206. Epub 2018 Jun 19. PubMed PMID: 29920138
75. Wolff AC, Hammond MEH, **Allison KH**, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Arch Pathol Lab Med.* 2018 May 30. doi: 10.5858/arpa.2018-0902-SA. [Epub ahead of print] PubMed PMID:29846104.
76. Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. Reply to C. Murray et al and V. Martin et al. *J Clin Oncol.* 2018 Oct 22;JCO1801163. doi:10.1200/JCO.18.01163. [Epub ahead of print] PubMed PMID: 30346904. *Arch Pathol Lab Med.* 2019 Jan 3. doi: 10.5858/arpa.2018-0906-LE. [Epub ahead of print] PubMed PMID: 30605367.
77. Bui MM, Riben MW, Allison KH, Chlipala E, Colasacco C, Kahn AG, Lachetti C, Madabhushi A, Pantanowitz L, Salama ME, Stewart RL, Thomas NE, Tomaszewski JE, Hammond ME. Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of

American Pathologists. Arch Pathol Lab Med. 2019 Jan 15. doi: 10.5858/arpa.2018-0378-CP.[Epub ahead of print] PubMed PMID: 30645156.

Case Reports

1. **Allison KH**, Mann GN, Norwood TH, Rubin BP. An unusual case of multiple giant myelolipomas: clinical and pathogenetic implication. *Endocr Pathol* 2003; 14:93-100.
2. **Allison K**, Clarridge JE 3rd. Long-term respiratory tract infection with canine-associated *Pasteurella dagmatis* and *Neisseria canis* in a patient with chronic bronchiectasis. *J Clin Microbiol* 2005; 43:4272-4274.
3. **Allison KH**, Love JE, Garcia RL. Epithelioid trophoblastic tumor: review of a rare neoplasm of the chorionic-type intermediate trophoblast. *Arch Pathol Lab Med* 2006; 130:1875-1881.

Invited Reviews

1. **Allison KH**, Tenpenny E, Reed SD, Swisher EM, Garcia RL. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. *Appl Immunohistochem Mol Morphol* 2008; 16:329-343.
2. Simonson WTN, **Allison KH**. Tumor infiltrating lymphocytes in cancer: implications for the diagnostic histopathologist. *Diagnostic Histopathology* February 2011; 17(2): 80-90.
3. **Allison KH**. Molecular Pathology of Breast Cancer: What a Pathologist Needs to Know. *Hum Pathol* 2012 Jan; 42(1):41-50.
4. **Allison KH**, Sledge GW. Heterogeneity and Cancer. *Oncology (Willison Park)*. 2014 Sep;28(9):772-8. Review.
5. Lin CY, Barry-Holson KQ, **Allison KH**. Breast cancer stem cells: are we ready to go from bench to bedside? *Histopathology*. 2016 Jan;68(1):119-37. doi: 10.1111/his.12868. Review.
6. **Allison KH**. Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual, and Borderline Results. *Surg Pathol Clin*. 2018Mar;11(1):147-176. doi: 10.1016/j.path.2017.09.006. Review. PubMed PMID:29413654.

Invited Book Chapters

1. **Allison KH**, Lawton TJ: Papillary lesions. *In* Breast, Lawton TJ, ed. Illustrated Surgical Pathology, Weiss L, series editor (New York: Cambridge University Press, 2009), pp 67-80.
2. **Allison KH** and RD Cardiff: Mammary Gland. *In* Comparative Anatomy and Histology: A Mouse and Human Atlas, Dintzis SM and Treuting PM ed. (Elsevier, 2012) pp 41-52.
3. Calhoun KE, Korde LA, **Allison KH**, DeMartini W, Li CI, Anderson BO: Clinical Management of Lobular Carcinoma in Situ. *In* Advanced Therapy of Breast Disease (People's Medical Publishing House, 2012) pp 371-391
4. Calhoun KE, Allison KH, Kim JN, Rahbar H, Anderson BO. Phyllodes Tumors. *In* Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Osborne KC. (Wolters Kluwer Health, 2014) pp 826-837.
5. **Allison KH** and Jensen KC. Intraductal Proliferations (DCIS, ADH, and IDH) *In* A Comprehensive Guide to Core Needle Biopsies of the Breast, Sandra J. Shin, ed. (Springer, 2016) ISBN: 978-3-319-26289-5 (Print) 978-3-319-26291-8 (Online) pp. 337-375.
6. Jensen KC and **Allison KH**. Current Standard Predictive Markers. *In* A Comprehensive Guide to Core Needle Biopsies of the Breast, Sandra J. Shin, ed. (Springer, 2016) ISBN: 978-3-319-26289-5 (Print) 978-3-319-26291-8 (Online) pp 785-802
7. **Allison KH**. Molecular Testing in Breast Cancer. *In* Diagnostic Molecular Pathology, Coleman WB and Tsongalis GJ. (Elsevier, Nov 2016)
8. **Allison KH** and Mohsin SK. Gross Examination of Breast Specimens. *In* Breast Pathology, Second edition, David J Dabbs, ed. (Elsevier, Dec 2016)

Invited Editorials

1. **Allison KH**. Estrogen receptor expression in breast cancer: we cannot ignore the shades of gray. *Am J Clin Pathol* 2008; 130:853-854.

Letters to the Editor

1. Kohr JR, Eby PR, **Allison KH**, DeMartini WB, Gutierrez RL, Peacock S, Lehman CD. Identifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy (authors' reply). *Radiology* 2010; 257:839-840. [see also 19. above].

2. Wolff AC, Hammond ME, Hicks DG, **Allison KH**, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Dowsett M, McShane LM, Hayes DF. Reply to E.A. Rakha et al. *J Clin Oncol* 2015 Apr 10;33(11):1302-4. doi: 10.1200/JCO.2014.59.7559. Epub 2015 Mar 9.

Invited Book Reviews

1. **Allison KH**. O'Malley FP, Pinder SE. Breast Pathology. *Am J Clin Pathol* 2007;127:652.
2. **Allison KH**. Schnitt SJ, Collins LC. Biopsy interpretation of the breast. *Am J Clin Pathol* 2009

Books

1. **Allison KH**. *Red Sunshine: A Story of Strength and Inspiration from a Doctor Who Survived Stage 3 Breast Cancer* Paperback: 192 pages Publisher: Hatherleigh Press (September 27, 2011) Language: English ISBN-10: 1578264073 ISBN-13: 978-1578264070 www.redsunshine.org
2. Currently working on single author textbook on breast pathology, *Case Studies in Breast Pathology*; book contract with Cambridge University Press

ABSTRACTS/PLATFORM PRESENTATIONS:

2018 San Antonio Breast Cancer Symposium

Does Hormone Expression by IHC predict ER Pathway Activity? An Analysis in A Metastatic Breast Cancer Patient Cohort.

Soo-Ryum Yang¹, Anja van de Stolpe², Anne van Brussel², Henk van Ooijen², Alfiia Galimzianova³, David M Cohn³, Francisco Becal¹, Daniel L Rubin³, Kimberly H Allison¹

¹Stanford University School of Medicine, Dept of Pathology, Stanford, CA, USA, ²Precision & Decentralized Diagnostics, Philips Research, Eindhoven, The Netherlands

³Stanford University School of Medicine, Dept of Biomedical Data Science, Radiology, and Medicine, Stanford, CA, USA

Poster presentation

Development of a machine learning-based classifier for Oncotype DX prediction in breast carcinoma patients

Beca F1, Yang SR¹, Galimzianova A², Gruber JJ³, Wen HY⁴, Rubin DL², Allison KH¹.

1 - Department of Pathology, Stanford University School of Medicine, Stanford, CA

2 - Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA

3 - Division of Medical Oncology, Stanford University Medical Center, Stanford, CA

4 - Memorial Sloan Kettering Cancer Center, New York City, NY

Poster Presentation

2018 USCAP Annual Meeting, Vancouver, Canada

[2663] Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean

HER2 signals /cell >6.0 by FISH; A Multi-Institutional Study

Authors: Morgan Ballard, Mirna Toukatly, Gregory Bean, Florencia Jalikis, Gregor Krings, Rodney Schmidt, Yunn-Yi Chen, Mara Rendi, Suzanne Dintzis, Megan Troxell, Robert West, Richard Sibley, Kimberly H. Allison

Platform Presentation

911] Clinicopathologic Features, Management and Outcomes of Breast Secretory Lesions with and without Atypia

Authors: Kelly Mooney, Chieh-Yu Lin, Richard Sibley, Mara Rendi, Kimberly H. Allison

Poster Presentation

[2509] Potential Impact of Proposed HER2 FISH Guideline Updates on FISH results; A Multi-Institutional Study

Authors: Morgan Ballard, Wendy MacKerricher, Florencia Jalikis, Gregor Krings, Rodney Schmidt, Yunn-Yi Chen, Mara Rendi, Suzanne Dintzis, Megan Troxell, Robert West, Richard Sibley, Kimberly H. Allison

Poster Presentation

[1895] The clinicopathologic and genomic features of fibrotic foci in breast cancer - results from the TCGA cohort

Authors: Francisco Beca, Julia Tsang (Prince of Wales Hosp), Kristin C. Jensen, Kimberly H. Allison, Gary Tse (Prince of Wales Hosp)

Platform Presentation

2017 USCAP Annual Meeting, San Antonio, TX

[111] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"

Authors: Morgan Ballard, Megan Troxell, Kristin Jensen, Kimberly H Allison

Poster Session V #28, Wednesday Morning

[112] Breast Cancers with HER2 and CEP17 "Co-Amplification" by FISH: Pathologic Features and Clinical Outcomes

Authors: Morgan Ballard, Megan Troxell, Kristin Jensen, Kimberly H Allison

Poster Session V #26, Wednesday Morning

[2032] Comparison of Breast Carcinoma Nottingham Grading by Glass Slides versus Digital Whole Slide Images: Variability Increases Using Digital Format

Authors: Tara M Davidson, Mara H Rendi, Paul D Frederick, Tracy Onega, Kimberly H Allison, Ezgi Mercan, Tad T Brunyć, Linda G Shapiro, Donald L Weaver, Joann G Elmore

Proffered Papers: SECTION G, Monday Afternoon

2016 San Antonio Breast Cancer Symposium, San Antonio, TX

Milky Way Sign: A potential predictive sign of breast cancer on digital tomosynthesis

Authors: Miyake KK, Lipson JA, Allison KH, XU Y, Downey JR, Ikeda DM.

Poster presentation (**Dr Allison presenting**) Dec 8th, 2016

2016 USCAP Annual Meeting, Seattle, WA

[114] HER2 FISH Equivocal Category: Does Retesting Resolve This Clinical Grey Zone?

Authors: Morgan Ballard, Sucheta Srivastava, Robert B West, Kristin C Jensen, Richard K Sibley, Kimberly Allison

March 15, 2016, 9:15 am PLATFORM

[1973] Validation of Digital Whole Slide Imaging System for Intraoperative Breast Sentinel Lymph Node Touch Prep Analysis: A Single Institution Experience

Authors: Jenny Hoffmann, Lisa McGinnis, Chrisy T Mafnas, Jennifer Ziskin, Ann K Folkins, Kimberly Allison, Robert B West, John P Higgins, Neeraja Kambham, Steven R Long, Brent Tan

March 16, 2016, 9:30 am POSTER

2015 USCAP Annual Meeting, Boston, MA

[128] Characterization of Breast Cancers With Equivocal and Non-Classical HER2 FISH Results – A Multi-Institutional Study

Authors: Morgan Ballard, Florencia Jalikis, Gregor Krings, Rodney A Schmidt, Yunn Yi Chen, Mara H Rendi, Suzanne M Dintzis, Kristin C Jensen, Robert B West, Richard K Sibley, Kimberly H Allison
Date/Time: Tuesday, March 24, 2015 - 8:45 AM PLATFORM

[119] Histologic Features Associated With Diagnostic Disagreement in Atypical Ductal Hyperplasia of the Breast: Results From the B-Path Study

Authors: Kimberly H Allison, Mara H Rendi, Donald L Weaver, Joann Elmore
Session Info: Proffered Papers: Section SECTION B, Monday Morning POSTER

[138] Percent of Breast Cancers Positive for HER2 Varies By Ethnicity and Social Determinants of Health in California – Implications of Patient Demographics on Laboratory Benchmarks

Authors: Eugene Carneal, Daphne Y Lichtensztajn, Tina C Dur, Scarlett L Gomez, Kristin C Jensen, Allison W Kurian, Kimberly H Allison
Session Info: Poster Session I # 22, Monday Morning POSTER

2014 USCAP Annual Meeting, San Diego, CA

[129] HER2 Positive Rates Vary by County and Geographic Region in California Independent of Stage and Age at Presentation

Authors: Kimberly H Allison, Kristin C Jensen, Tina C Dur, Scarlett L Gomez, Robert B West, Allison W Kurian
Session Info: **Proffered Papers:** Section B, Tuesday Afternoon

[147] Can We Predict Which Her2 Tests Change from Biopsy to Excision?

Authors: Ryanne A Brown, Michael R Clay, Kristin C Jensen, Robert B West, Kimberly H Allison
Session Info: Poster Session I Stowell-Orbison/Surgical Pathology/Autopsy Awards Poster Session

[158] Dual IHC and FISH Testing to Identify HER2 Positive Subpopulations in Breast Cancer: Uncovering Heterogeneity

Authors: Michael R Clay, Kimberly H Allison, Kristin C Jensen
Session Info: Poster Session IV # 81, Tuesday Afternoon

[324] HER2 Heterogeneity by FISH in Breast Cancers and Matched Lymph Node Metastases: How Different Are They?

Authors: Carlos J Suarez, Rodney A Schmidt, Suzanne M Dintzis, Mara H Rendi, Kristin C Jensen, Robert B West, Kimberly H Allison
Session Info: Poster Session I Stowell-Orbison/Surgical Pathology/Autopsy Awards Poster Session # 53, Monday Morning

[1151] Risk of Secondary Malignancy (Including Breast) in Patients with Mismatch Repair Deficiency

Authors: Michael R Clay, Kimberly H Allison, Ann K Folkins, Teri A Longacre
Session Info: Poster Session I Stowell-Orbison/Surgical Pathology/Autopsy Awards Poster Session # 181, Monday Morning

2013 Annual USCAP meeting, Baltimore, MD

- Kathi H Adamson, Eric Q Konnick, Suzanne M Dintzis, Mara H Rendi, Hannah M Linden, **Kimberly H Allison**. [To Count or Not To Count? Scoring Ki67 in Breast Cancers According to International Working Group Recommendations](#). **Platform presentation**
- **Kimberly H Allison**, Yunn-Yi Chen, Susan C Lester, Nicole B Johnson, Rachel E Factor, Gary MK Tse, Sandra J Shin, David A Eberhard, Puay Hoon Tan, Stuart J Schnitt, Laura C Collins, Kristin C Jensen, Konstanty Korski, Fredrick M Waldman, Andrew H Beck [Host Inflammation and Breast Cancer Molecular Subtypes: Results from a TCGA Sub-Analysis](#). **Platform presentation**

- Mark R Kilgore, Julie S Kranseler, Suzanne M Dintzis, Rodney A Schmidt, Paul E Swanson, Mara H Rendi, Hannah M Linden, **Kimberly H Allison** [Phenotypes of Breast Cancers Heterogeneous for HER2 Gene Amplification: Looking for Biologically Relevant Thresholds](#). **Poster presentation**
- Tracy Onega, **Kimberly H Allison**, Natalia Ostler, Joann Elmore, Donald L Weaver. [Digitized Whole Slides for Breast Pathology Interpretation: Pathologists Use and Perceptions](#). **Poster presentation.**
- Michael A Seidman, Susan C Lester, Nicole B Johnson, **Kimberly H Allison**, Yunn-Yi Chen, Rachel E Factor, Gary MK Tse, Sandra J Shin, David A Eberhard, Puay Hoon Tan, Stuart J Schnitt, Laura C Collins, Kristin C Jensen, Konstanty Korski, Frederic M Waldman, Andrew H Beck. [Integrative Genomic Profiling To Identify Drivers of Breast Cancer-Associated Inflammation](#). **Poster presentation.**
- Kathi H Adamson, **Kimberly H Allison**, Paul E Swanson, Suzanne M Dintzis, Mara H Rendi. [Unexpected PAX8 Reactivity in Metastatic High Grade Breast Cancer](#). **Poster presentation.**

2012 Annual USCAP meeting, Vancouver, Canada

- Adamson KH, Dintzis SM, Schmidt RA, Mankoff D, **Allison KH**. Breast cancer HER2 heterogeneity by FISH pre and post neoadjuvant chemotherapy: A pilot study. **Poster presentation**
- Rendi M, Allison KH, Stern J, Hawes S, Feng Q, Kiviat N. Breast cancer subtypes and epigenetic characterization of women from Senegal, West Africa. **Poster presentation**
- Suarez CJ, Dintzis SM, Schmidt RA, **Allison KH**. HER2 heterogeneity by FISH in breast cancers and matched lymph node metastases: A pilot study. **Poster presentation**

2011 American Society of Clinical Oncologists in Chicago, IL

- Loiselle CR, Eby PR, Kim JN, Calhoun K, **Allison KH**, Gadi VK, Peacock S, Storer B, Mankoff D, Partridge S, Lehman CD. Can pre-operative dynamic contrast enhanced breast MRI predict extensive occult axillary lymph node metastases in patients with positive sentinel node biopsy? **Poster presentation**

2011 Annual USCAP meeting, San Antonio, TX

- **KH Allison**, SM Dintzis, RA Schmidt. Frequency of HER2 Heterogeneity by Fluorescence in Situ Hybridization According to CAP Expert Panel Recommendations; Time for a new look at how to report heterogeneity. **Platform Presentation**
- SM Dintzis, **KH Allison**, RA Schmidt. FISH Testing for HER2 Expression May Yield Discordant Results Depending on Reporting Criteria Used. **Poster Presentation**
- RA Schmidt, , SM Dintzis, **KH Allison**. High-ICR": A Unifying Data-Driven Reporting System for Her2 FISH Analysis Based on Intra-Tumor Heterogeneity. **Poster Presentation**

2010 San Antonio Breast Cancer Symposium, San Antonio, TX

- **KH Allison**, SM Dintzis, RA Schmidt. Analysis of College of American Pathologists Recommendations for Reporting HER2 Intra-tumoral heterogeneity (ITH) on 1329 Breast Cancers. **Poster Presentation**

- SM Dintzis, **KH Allison**, RA Schmidt. HER2 Testing by FISH: Discordance between HER2 Signals per Cell and HER2:CEP17 ratio. **Poster Presentation**
- RA Schmidt, **KH Allison**, SM Dintzis. Quantification of Intra-tumoral Heterogeneity for HER2 Gene Amplification by FISH with Proposed New (High ICR) Reporting System. **Poster Presentation**

2010 99th Annual USCAP meeting, Washington DC:

- **KH Allison**, SM Dintzis, PL Kandalaf, AM Gown, LC Goldstein. Can Pathologic Features and Immunophenotype of ER+, Node Negative Breast Cancers Identify High and Low Risk OncotypeDX Subgroups? **Poster Presentation** SM Dintzis, **KH Allison** Effect of Formalin Fixation Time on Her 2 Expression by Immunohistochemical Technique. **Poster Presentation**
- M Rendi, **KH Allison**, P Sow, P Toure, A Dem, S Hawes, Q Feng, N Kiviati Histologic and Epigenetic Characterization of Pre- and Postmenopausal Breast Cancer from Women in Senegal, West Africa. **Poster Presentation.**
- MH Rendi, SM Dintzis, PR Eby, KE Calhoun, **KH Allison** Upgrade Rates of Lobular Neoplasia on Core Needle Biopsy: Should Atypical Lobular Hyperplasia Be Routinely Excised? **Poster Presentation.**
- JM Wu, AH Beck, D Witten, **K Allison**, M van de Rijn, RB. West Fibroblast-Like Stromal Response Is Host-Dependent While Macrophage-Associated Stromal Response Is Tumor-Dependent: A Study of Stromal Response in Paired Breast Carcinomas from Patients with Dual Primaries. **Poster Presentation**

2010 American Society of Breast Surgeons Annual Meeting, Las Vegas, NV

- SH Javid, **KH Allison**, KE Calhoun, GN Mann, DR Byrd, and BO Anderson. Diagnostic Excision is Warranted for Pleomorphic Lobular Carcinoma In Situ.
- KE Calhoun, **KH Allison**, SH Javid, GN Mann, DR. Byrd, R Schmidt, BO Anderson. Axillary Sentinel Lymph Node Dissection for Invasive Breast Cancer and the Current AJCC Staging Guidelines: Pathology Results of 877 Cases and the Impact on Subsequent Axillary Management.

2009 98th Annual USCAP meeting, Boston, MA:

- EE Grimm, RA Schmidt, PE Swanson, **KH Allison**. Achieving 95% IHC/FISH concordance for Her2: Causes and implications of discordant cases. **Poster Presentation**
- **KH Allison**, PR Eby, J Kohr, WB DeMartini, CD Lehman. Can we predict which cases of atypical ductal hyperplasia on core needle biopsy will upgrade? **Poster Presentation**
- **KH Allison**, SD Reed, K Upson, LF Vopigt, CD Jordan, KM Newton, RL Garcia. Loss of PAX-2 expression is a sensitive marker for neoplastic endometrium. **Poster Presentation**

2008 97th Annual USCAP meeting, Denver, CO:

- Bohling S, T Lawton, **KH Allison**. Immunosuppressive regulatory T cells are associated with more aggressive breast cancer phenotypes: a potential therapeutic target. **Poster presentation**

2007 96th annual USCAP meeting, San Diego, CA:

- **Allison KH**, CA Shah, RL Garcia, EM Swisher. Does type and degree of T cell immune response to ovarian cancer matter? Correlation of cytotoxic T cells and FoxP3+ immunosuppressive Tregs with survival. *Modern Pathology*. 2007 Feb; Vol 20(2s) Abstract #855. **Platform presentation** at 2007 96th annual USCAP meeting, San Diego, CA.
- **Allison KH**, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL. Diagnosing endometrial hyperplasia: Why is it so difficult to agree? *Modern Pathology*. 2007 Feb; Vol 20(2s) Abstract #854. **Poster presentation** at 2007 96th annual USCAP meeting, San Diego, CA.

2006 95th annual USCAP meeting, San Antonio, TX:

- **Allison KH**, Swisher EM, Garcia RL. Volume of borderline change in ovarian neoplasms: Do cystadenomas with focal borderline change warrant a full operative staging? *Modern Pathology*. 2006 Jan; Vol 19(s), Abstract #789. **Poster presentation** at 2006 95th annual USCAP meeting, San Antonio, TX.
- **Allison KH**, Swanson PE, Lawton TJ. Hormone receptor and Her2/neu status pre and post neoadjuvant chemotherapy: Should immunohistochemical studies be repeated? *Modern Pathology*. 2006 Jan; vol 19 (s), Abstract #80. **Platform presentation** at 2006 95th annual USCAP meeting, San Antonio, TX.

Other Meetings:

- JZ Press, **KH Allison**, R Garcia, H Tamimi, H Gray, R Swenson, B Goff. Vulvar Paget's is characterized by increased FOXP3: Would Imiquimod be useful? **Platform presentation** at June, 2008 Western Association of Gynecologic Oncologists meeting, Sonoma, CA.
- Pugliese M, **KH Allison**, R Tickman, D Beatty. Microstaging of Sentinel Lymph Node Biopsies is Not Associated with Disease-Free Survival in Breast Cancer. **Poster presentation** at 2007 American College of Surgeons Clinical Congress in New Orleans.
- **Allison KH**, R.E. Swensen. FoxP3+ regulatory T cells are present in significant numbers in high grade VIN: A potential immunotherapy target. **Platform presentation** at June, 2007 Western Association of Gynecologic Oncologists meeting, Sun River, OR.
- Norquist B, Garica R, **Allison KH**, Goff B, Swisher E. Identification of preneoplastic alterations in tubal epithelium of women with hereditary peritoneal and ovarian carcinomas. **Platform presentation** at June, 2007 Western Association of Gynecologic Oncologists meeting, Sun River, OR.

TALKS/COURSES

January 2019	USCAP Interactive Course: A Practical Approach to Problematic Breast Lesions Topics: <i>Papillary Lesions, Mimics of Invasion</i> Palm Springs, CA
October 2018	<i>The Spectrum of Atypical Breast Pathology: Risk Factor or Cancer Precursor?</i>

- Course on Atypical Breast Lesions for American College of Surgeons Clinical Congress, Boston, MA
- Sept 2018 *Ancillary Prognostic and Predictive Testing in Breast Cancer: Focus on Discordant, Unusual or Borderline Results*
And
Problematic Non-Invasive Lesions on Core Biopsy
- Sept 2018 Taipei International Breast Cancer Symposium, Taipei, Taiwan
HER2 and Hormone Receptor Testing in Breast Cancer: Latest Updates and Remaining Questions
- March 2018 Invited Grand Rounds Speaker, UCLA Dept of Pathology
Keynote Speaker at NCBC 2018, 28th Annual Interdisciplinary Breast Center Conference, Las Vegas, NV
From Professional to Personal: My journey on the other side of the microscope
Diagnostic Agreement in Breast Pathology: When to consider a second opinion on pathology
- Nov 2017 Invited featured speaker at Singapore General Hospital Breast Pathology Course and Asian Breast Diseases Association Annual Scientific Meeting. Singapore.
- Sept 2017 Keynote speaker for Association of Pathology Assistants Annual Meeting, San Antonio Texas.
- July 2017 Scientific Symposia 3rd Annual Dr. Richard L. Kempson
Diagnostic Pathology Course: Making Diagnoses that Matter: the Next Generation of Problem Areas in Breast, GI, GYN and Placenta Pathology. Invited speaker for five CME talks on breast pathology. Maui, Hawaii
- May 2017 *Updates in Breast Cancer Pathology Best Practices: Be a Diagnostic Oncologist*
Invited speaker for University of Chicago Dept of Pathology Pathobiology Series. Chicago, IL
- March 2017 *Workshop on Intraductal Proliferative Lesions of the Breast*
United States and Canadian Academy of Pathology (San Antonio, TX, Short Course)
- Nov 2016 Short course: *Atypical Intraductal Proliferative Lesions of the Breast; Test Yourself!*
Evening slide session: *Breast Pathology Diagnoses Not to Miss*
Moderated Case seminar: *Diagnostic Problems in Surgical Pathology*
California Society of Pathology Annual CME Meeting
San Francisco, CA
- Sept 2016 *Breast Cancer Pathology Diagnostics in the Era of Personalized Medicine and Precision Health*
Stanford Comprehensive Cancer Research Training Program, Menlo Park, CA
- Sept 2016 *Keep it Simple: Understanding Breast Cancer, Invasion and Metastasis*
Bridging Gaps in Breast Cancer: A forum for mental health providers, Stanford, CA

April 2016 *Diagnostic Agreement in Breast Pathology: Can We Improve?*
Grand Rounds, Baylor Medical Center, Houston, TX

April 2016 *Molecular Classification of Breast Cancers*
Evaluation of Proliferation Markers in Breast Cancer
Red Sunshine: My Breast Cancer Journey as a Breast Pathologist
Houston Society of Clinical Pathology, 57th Annual Spring
Symposium. Houston, TX

April 2016 *Understanding your pathology report: Lessons in Radiology-
Pathology Correlation*
Society of Breast Imaging Annual Meeting
Austin, TX

March 2016 *Workshop on Intraductal Proliferative Lesions of the Breast*
United States and Canadian Academy of Pathology (Seattle, WA,
Short Course)

Feb 2016 Speaker at the Scientific Symposiums International CME course:
*Surgical Pathology Essentials in GI, Pancreaticobiliary,
Gynecological, Breast and Hematopathology*
Kona, HI
Talks given:
*1-2. Problematic non-invasive lesions of the breast (Parts 1&2):
Test yourself!*
*3. Are you ready for breast tumor board? Understanding the
impact of your diagnosis and navigating common clinical
questions in breast cancer*
*4. The Pathologist as “Diagnostic Oncologist:” Getting predictive
markers in breast pathology right*
5. Challenging breast pathology cases seen in consultation

Sept 2015 [*The Most Important Doctor You May Never Meet*](#)
Keynote Speaker at “Breast Cancer Today: Individual Treatments,
Shared Experiences,” Living Beyond Breast Cancer Annual
Conference, Denver, CO

Sept 2015 *Workshop on Intraductal Proliferative Lesions of the Breast*
Webinar for Kaiser Southern California

July 2015 *Understanding Breast Cancer: From Pathology to Personal
Perspectives*
Cancer Prevention Institute of California, Annual Registrars
Meeting, Fremont, CA

May 2015 *Understanding Breast Cancer Biology: New Discoveries and
Treatment Advances*
Stanford Medicine Community Day “Heath Matters”

March 2015 *Workshop on Intraductal Proliferative Lesions of the Breast*
United States and Canadian Academy of Pathology (Boston, MA,
Short Course)

January 2015 *Atypical lesions of the breast*
Webinar for Kaiser Permanente Northern California/Stanford
Series

January 2015 *HER2 IHC Test Interpretation in Breast Cancer*
Online Course with Self-Assessment Module

Breast Predictive Factors Learning Series
College of American Pathologists

November 2014
-*Intraductal Proliferative Lesions of the Breast*
-*Workshop on Challenges in Breast Cancer Predictive Marker Interpretation*
-*Understanding the Clinical Impact of your Diagnosis: Lessons Learned from the Other Side of the Microscope*
Invited speaker (3 talks) for Arizona Society of Pathologist's Fall Meeting, Phoenix, AZ

October 2014
Management of High Risk Lesions of the Breast
Invited speaker at 2014 American College of Surgeons Clinical Congress: "High-Risk Breast Cancer Management from A to Z" San Francisco, CA

September 2014
Atypical lesions of the breast
Invited speaker at Kaiser's MidAtlantic Permanente Medical Group Annual Radiology CME Conference "Hot Topics in Breast Imaging," Washington D.C

July 2014
Intraductal Proliferative Lesions of the Breast
Webinar for Kaiser Permanente California/Stanford Series

May 2014
[*Pathology's Role in Cancer Care: The Most Important Doctor You Don't Know*](#)
Invited speaker at REV Forum on Cancer Care, Washington DC
Blog: "[The Most Important Doctor You Don't Know](#)"

March 2014
"*When the doctor becomes the patient: Cancer from both sides of the microscope*"
[Stanford Medical School 101](#), Stanford, CA

November 2013
HER2 Testing in Breast Cancer: A Practical Guide to Interpretation and Approaching Challenging Cases
Live webinar for American Society of Clinical Pathology

November 2013
Advances in Understanding the Biology of Breast Cancer
Keynote speaker for 10th Annual Breast Cancer Conference for Breast Cancer Connections, Oracle Conference Center, Redwood City, CA

November 2013
Understanding Breast Cancer
Invited speaker for Stanford School of Medicine Facilities Monthly Conference

October 2013
DCIS: Is it a Precursor or Risk Lesion?
CME course: "Challenges and Controversies in Breast Cancer"
Bell Harbor Conference Center, Seattle, WA

March 2013
[*Understanding Breast Cancer: A Breast Cancer Pathologist Learns from Life on the Other Side of the Microscope*](#) and
[*Surviving Breast cancer: A Pathologist and Patient's Perspective*](#)
Keynote speaker for Komen Oregon and SW Washington Breast Cancer Issues Conference, Portland, OR

August 2013
Seeing cancer from both sides
Stanford Medicine 1:2:1 [Podcast/Interview](#)

November 2012
Advancing Patient-Centered Care for Women Across Our Globe: The Laboratory is Part of the Puzzle

Panel and speaker at the American Society of Clinical Pathology Annual Meeting, Boston, MA
 October 2012 *Understanding the Clinical Impact of Your Diagnosis: Lessons learned from the other side of the microscope*
 The Chicago Pathology Society Lecture Series, Chicago, IL
 September 2012 *Misconceptions in Breast Cancer Diagnosis: A Pathologist's Perspective* and *Surviving Breast Cancer: Lessons Learned*
 Cancer for Primary Care: Shifting Perspectives on Evidence and Advocacy, CME Course
 Providence Alaska Medical Center, Anchorage, Alaska
 June 2012 *The Evolving Practice of Predictive Testing in Breast Cancer*
 Stanford University, CA
 May 2012 Keynote speaker for Seattle Magazine's "Seattle Top Doctors" awardees event
 April 2012 *Personalizing Treatment Decisions: Quality HER2 and BRAF Testing*
 Washington Adventist Hospital Grand Rounds, Washington D.C.
 Genentech Speakers Bureau
 March 2012 *Breast Pathology Evening Specialty Conference Case Presentation*
 United States and Canadian Academy of Pathologists Annual Meeting, Vancouver, Canada
 March 2012 *Surviving Cancer, Lessons Learned from a Physician Who Became a Patient*
 Puget Sound Oncology Nursing Society Symposium and Bastyr University
 February 2012 *Delivery of Personalized Medicine: A Professional and Personal Perspective*
 Genentech/Roche Legal Conference, Monterey, CA
 February 2012 *From Physician to Patient: Lessons Learned on the Other Side of the Microscope*
 Seattle Cancer Care Alliance Board Presentation, Seattle, WA
 January 2012 *HER2 Testing; A Professional and Patient Perspective*
 Genentech National Sales Convention, Las Vegas, NV
 October 2011 *A Breast Cancer Pathologist Learns from Life on the Other Side of the Microscope*
 Marin General Hospital/Center for Integrative Health and Wellness
 October 2011 *The Path of a Breast Cancer Survivor*
 UW Medicine and Seattle Public Library Lecture Series
 October 2011 Moderator for *Metastatic Breast Cancer* session
 CME course: "Challenges and Controversies in Breast Cancer"
 Bell Harbor Conference Center, Seattle, WA
 April 2011 *Breast Cancer Testing: From Arbitrary to Evidence-Based*
 Pathology Presents, UWMC, Seattle, WA
 May 2010 *Practicing Breast Pathology in 2010: How can we meet guidelines?*
 Pacific Northwest Society of Pathology Meeting
 Fred Hutchinson Cancer Research Center, Seattle, WA
 June 2010 *Lobular Neoplasia on Core Needle Biopsy*

Fred Hutchinson/University of Washington Cancer Consortium
Clinical Breast Cancer Faculty Retreat, Seattle Cancer Care Alliance

May 2010 *UW Mini-Medical School Series: Is your doctor really hearing you, part : Physician panel on being a patient*

March 2010 *UWMC Mini Medical School Series, featured on UWTV*
OncotypeDX Testing in Breast Cancer: Do all ER+, Lymph Node Negative Patients Need to be Tested?
Fred Hutchinson/University of Washington Cancer Consortium
Clinical Breast Cancer Faculty Retreat, Seattle Cancer Care Alliance

October 2009 *The Pathologic Spectrum of Triple Negative and Basal-Like Breast Cancers*
CME course: “Challenges and Controversies in Breast Cancer”
Bell Harbor Conference Center, Seattle, WA
Sponsored by: UWMC/Fred Hutchinson/Seattle Cancer Care Alliance

October 2009 *Molecular Testing in Breast Cancer: Will it become standard practice?*
Northwest Medical Laboratory Symposium
DoubleTree Inn, Seattle-Tacoma Airport, Seattle, WA

June 2009 *Sentinel Lymph Node IHC Staining*
Fred Hutchinson/University of Washington Cancer Consortium
Clinical Breast Cancer Faculty Retreat, Seattle Cancer Care Alliance

March 2009 *Molecular Testing in Breast Cancer: Will it become Standard?*
Grand Rounds, Laboratory Medicine
University of Washington Medical Center
<http://www.youtube.com/watch?v=G--b-dV65ho>

November 2008 *Correlation between core needle biopsy and final surgical excision in Breast Cancer*
Fred Hutchinson/University of Washington Cancer Consortium
Clinical Breast Cancer Faculty Retreat, Seattle Cancer Care Alliance

Annual since 2008 *Introduction to Breast Pathology*
University of Washington Medical Center, Lecture to Medical Students

Annual since 2007 *Breast Pathology*
University of Washington Medical Center, Lecture to Pathology Residents

October 2007 *The New CAP/ASCO Her2/neu guidelines*
CME course: “Challenges and Controversies in Breast Cancer”
Bell Harbor Conference Center, Seattle, WA
Sponsored by: UWMC/Fred Hutchinson/Seattle Cancer Care Alliance

May 2007 *Pathology of Paget’s Disease of the Breast*
Fred Hutchinson/University of Washington Cancer Consortium

March 2007	Clinical Breast Cancer Faculty Retreat, Seattle Cancer Care Alliance <i>The Uterus: Endometrial and Myometrial Pathology</i> University of Washington Medical Center, Lecture to Pathology Residents
October 2006	<i>Pathology of Predictive and Prognostic Markers in Breast Cancer: At Diagnosis IHC, FISH and OncotypeDX</i> Fred Hutchinson/University of Washington Cancer Consortium Clinical Breast Cancer Faculty Retreat, Seattle Cancer Care Alliance
August 2006	<i>Hormone Receptor and Her2/neu Status Pre and Post Neoadjuvant Chemotherapy in Breast Cancer: Should Immunohistochemistry be Repeated?</i> Fred Hutchinson/University of Washington Cancer Consortium Clinical Breast Cancer Faculty Retreat, Seattle Cancer Care Alliance
February 2006	<i>Gene Expression Profiling in Breast Cancer: Multiple applications changing the way we diagnose and treat.</i> University of Washington Dept of Laboratory Medicine Research and Development Rounds, UWMC

RESEARCH FUNDING:

Active

Exhibit B-26 (Demirci, Utkan - Project 124869)
Phillips Electronics North America Corp
Advancing Precision Health: Enabling Personalized Diagnostics and Treatment Delivery
09/01/2016 – 01/31/2019 0.60 calendar

MEDIA RELATED TO DR ALLISON:

Twitter: @DrKimAllison

Website for Dr Allison's book: *Red Sunshine*: <https://www.facebook.com/RedSunshineKim>
(Agent: Dede Cummings, agent and publicity, dcdesignsteamvt@gmail.com)

Most Recent PubMed articles by Dr Allison:
<http://www.ncbi.nlm.nih.gov/pubmed?term=Allison%20KH>

Front page feature in College of American Pathologist's CAP TODAY "[Small groups, big answers in HER2 testing](#)" By Karen Titus

Featured in College of American Pathologists "Targeted Cancer Therapy" Video
<http://yourpathologist.org> and
https://www.youtube.com/watch?v=4xxwV_AG15I&index=21&t=0s&list=PLXqw9q4QecZzaP53IqcYM1zAZnZUGuuAs

Stanford Medicine 1:2:1 [Podcast/Interview](#)

San Francisco Chronicle article [“For Cancer Specialists, Disease Can Make Them Better Doctors”](#) featuring Dr Allison

New York Times piece on Dr. Allison:

<http://www.nytimes.com/2011/10/11/health/11brody.html>

Interview with Dr Allison by American Society of Clinical Pathology for 2012 Annual Meeting <http://www.ascp.org/Newsroom/Breast-Cancer-Pathologist-Who-Survived-Breast-Cancer-Shares-Her-Story-at-the-2012-ASCP-Annual-Meetin.html>

Interview with Andrew Schorr, health care correspondent and author of The Web Savvy Patient: <http://www.patientpower.info/program/my-journey-from-pathologist-to-breast-cancer-survivor>

CNN piece on Dr Allison: http://www.cnn.com/2011/10/24/health/conditions/breast-cancer-nurse-pathologist/index.html?hpt=he_c1

New Day Northwest TV segment featuring Dr Allison: <http://www.king5.com/new-day-northwest/Seattle-Cancer-132528393.html>

2009 Lecture on *Molecular Testing in Breast Cancer: Will it become Standard?*

<http://www.youtube.com/watch?v=G--b-dV65ho>

National Association of Public Hospitals post: <http://www.naph.org/Main-Menu-Category/Newsroom/Safety-Net-Matters-Blog/When-the-Breast-Cancer-Diagnosis-is-Personal.aspx>